SHAREHOLDER ALERT: Nationally Ranked Investors' Rights Firm Holzer & Holzer, LLC Announces Investigation of Design Therapeutics, Inc. (DSGN)

ATLANTA, GA / ACCESSWIRE / December 29, 2022 / Holzer & Holzer, LLC is investigating whether Design Therapeutics, Inc. ("Design Therapeutics" or the "Company") DSGN complied with federal securities laws. On December 7, 2022, Design Therapeutics announced initial results from the Company's Phase 1 clinical trial in patients with Friedreich ataxia. As part of the initial results, the Company disclosed that "16 (73%) patients on DT-216 and eight (73%) patients on placebo reported at least one treatment-emergent adverse event." Following this disclosure, the Company's stock price dropped.

If you purchased Design Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at  cholzer@holzerlaw.com  or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website https://holzerlaw.com/case/design-therapeutics/  to discuss your legal rights.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. 

CONTACT: 

Corey Holzer, Esq. 
(888) 508-6832 (toll-free) 
cholzer@holzerlaw.com

SOURCE: Holzer & Holzer